North Star Asset Management Inc. Invests $10.58 Million in Repligen Corporation $RGEN

North Star Asset Management Inc. bought a new stake in Repligen Corporation (NASDAQ:RGEN – Free Report) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 77,561 shares of the biotechnology company’s stock, valued at approximately $10,582,000. North Star Asset Management Inc. owned about 0.14% of Repligen at the end of the most recent quarter.

Other institutional investors and hedge funds have also modified their holdings of the company. Bank of Nova Scotia acquired a new position in Repligen in the second quarter worth $3,547,000. Avidity Partners Management LP grew its holdings in shares of Repligen by 54.7% during the first quarter. Avidity Partners Management LP now owns 77,800 shares of the biotechnology company’s stock worth $9,166,000 after purchasing an additional 27,500 shares during the last quarter. American Capital Management Inc. acquired a new stake in shares of Repligen in the second quarter valued at $49,262,000. Global Retirement Partners LLC acquired a new stake in shares of Repligen in the second quarter valued at $655,000. Finally, B. Metzler seel. Sohn & Co. AG bought a new position in shares of Repligen in the second quarter valued at about $3,597,000. 97.64% of the stock is owned by institutional investors and hedge funds.

Get Repligen alerts:

Insider Activity

In other news, CFO Jason K. Garland sold 733 shares of the firm’s stock in a transaction dated Thursday, June 25th. The shares were sold at an average price of $145.00, for a total value of $106,285.00. Following the transaction, the chief financial officer owned 19,359 shares of the company’s stock, valued at approximately $2,807,055. This trade represents a 3.65% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 0.60% of the company’s stock.

Analyst Ratings Changes

Several brokerages recently issued reports on RGEN. Evercore reiterated an “outperform” rating and set a $160.00 price target on shares of Repligen in a research report on Monday, July 6th. JPMorgan Chase & Co. raised their price objective on shares of Repligen from $165.00 to $175.00 and gave the company an “overweight” rating in a research report on Wednesday, July 29th. Wells Fargo & Company boosted their target price on shares of Repligen from $180.00 to $185.00 and gave the stock an “overweight” rating in a research note on Thursday, July 30th. Zacks Research upgraded shares of Repligen from a “hold” rating to a “strong-buy” rating in a research report on Thursday, July 30th. Finally, Jefferies Financial Group reissued a “hold” rating and set a $142.00 price target on shares of Repligen in a research note on Tuesday, May 5th. Three research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $166.43.

Check Out Our Latest Analysis on RGEN

Repligen Trading Up 1.0%

Shares of RGEN opened at $182.03 on Friday. The company has a quick ratio of 7.64, a current ratio of 9.05 and a debt-to-equity ratio of 0.26. Repligen Corporation has a 12-month low of $100.99 and a 12-month high of $188.73. The firm has a market capitalization of $10.27 billion, a PE ratio of 249.36, a price-to-earnings-growth ratio of 3.29 and a beta of 1.03. The stock’s fifty day simple moving average is $151.11 and its 200-day simple moving average is $132.79.

Repligen (NASDAQ:RGEN – Get Free Report) last posted its quarterly earnings results on Tuesday, July 28th. The biotechnology company reported $0.54 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.45 by $0.09. The business had revenue of $204.13 million for the quarter, compared to analysts’ expectations of $201.59 million. Repligen had a return on equity of 5.30% and a net margin of 5.29%.The firm’s quarterly revenue was up 11.9% compared to the same quarter last year. During the same quarter last year, the business earned $0.26 earnings per share. Repligen has set its FY 2026 guidance at 2.030-2.090 EPS. As a group, research analysts predict that Repligen Corporation will post 2.06 earnings per share for the current year.

Repligen Company Profile

(Free Report)

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.

Read More

• Five stocks we like better than Repligen
• Nutanix’s Rally Has a Bigger Story Than Earnings as AMD’s AI Bet Takes Shape
• SEC Probe Puts Wall Street Leverage Risk Back in Focus
• A Bearish-Dollar Options Surge Raises the Stakes for Warsh at Jackson Hole
• Five Below’s Turnaround Is Working—But Has the Stock Run Too Far?

Want to see what other hedge funds are holding RGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Repligen Corporation (NASDAQ:RGEN – Free Report).

Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.